Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

Why the future remains bright for Riverton boys basketball despite 0-3 Sangamo start Results can be emailed to [email protected]. Griffin McClure went 8-for-11 from the floor and scored a game-high ...

The kidney transplant rejection prophylaxis market is projected to experience steady growth, driven by the introduction of innovative therapi ...

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...

Here are some before and after pictures of the company's wordmark and logo. Need a break? Play the USA TODAY Daily Crossword Puzzle. Here's a look at how the new wordmark and logo will appear on ...

Walmart is refreshing its logo for the first time in nearly two decades, highlighting its evolution while also serving as a nod to its past, the big-box retailer announced Monday. The word mark on ...

in a Sangamo Conference matchup with Pleasant Plains. “It really sucked not being able to play, but I think I worked hard to get better and I feel great.” Need a break? Play the USA TODAY ...